Resveratrol worsens survival in SCID mice with prostate cancer xenografts in a cell-line specific manner, through paradoxical effects on oncogenic pathways

Prostate

Volumn 73, Issue 7, 2013, Pages 754-762

  Klink, Joseph C ^a   Tewari, Alok K ^b   Masko, Elizabeth M ^b   Antonelli, Jodi ^b   Febbo, Phillip G ^c   Cohen, Pinchas ^d   Dewhirst, Mark W ^b   Pizzo, Salvatore V ^b   Freedland, Stephen J ^b,e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e DURHAM VA MEDICAL CENTER   (United States)

Author keywords

beta catenin; E2F3; IGF 1; prostate cancer; resveratrol; xenograft

Indexed keywords

RESVERATROL;

ANIMAL EXPERIMENT; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR XENOGRAFT;

ANIMALS; ANTIOXIDANTS; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; MALE; MICE; MICE, SCID; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; STILBENES; SURVIVAL ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84876293301     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22619     Document Type: Article

References (47)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60 (5): 277-300.
2. Wiygul JB, Evans BR, Peterson BL, Polascik TJ, Walther PJ, Robertson CN, Albala DM, Demark-Wahnefried W,. Supplement use among men with prostate cancer. Urology 2005; 66 (1): 161-166.
3. Frankel EN, Waterhouse AL, Kinsella JE,. Inhibition of human LDL oxidation by resveratrol. Lancet 1993; 341 (8852): 1103-1104.
4. Resveratrol. Monograph. Altern Med Rev 2010; 15 (2): 152-158.
5. Harper CE, Patel BB, Wang J, Arabshahi A, Eltoum IA, Lamartiniere CA,. Resveratrol suppresses prostate cancer progression in transgenic mice. Carcinogenesis 2007; 28 (9): 1946-1953.
6. Seeni A, Takahashi S, Takeshita K, Tang M, Sugiura S, Sato SY, Shirai T,. Suppression of Prostate Cancer Growth by Resveratrol in The Transgenic Rat for Adenocarcinoma of Prostate (TRAP) Model. Asian Pac J Cancer Prev 2008; 9 (1): 7-14.
7. Bishayee A,. Cancer prevention and treatment with resveratrol: From rodent studies to clinical trials. Cancer Prev Res (Phila) 2009; 2 (5): 409-418.
8. Zheng W, McLerran DF, Rolland B, Zhang X, Inoue M, Matsuo K, He J, Gupta PC, Ramadas K, Tsugane S, Irie F, Tamakoshi A, Gao YT, Wang R, Shu XO, Tsuji I, Kuriyama S, Tanaka H, Satoh H, Chen CJ, Yuan JM, Yoo KY, Ahsan H, Pan WH, Gu D, Pednekar MS, Sauvaget C, Sasazuki S, Sairenchi T, Yang G, Xiang YB, Nagai M, Suzuki T, Nishino Y, You SL, Koh WP, Park SK, Chen Y, Shen CY, Thornquist M, Feng Z, Kang D, Boffetta P, Potter JD,. Association between body-mass index and risk of death in more than 1 million Asians. N Engl J Med 2011; 364 (8): 719-729.
9. Longo VD, Fontana L,. Calorie restriction and cancer prevention: Metabolic and molecular mechanisms. Trends Pharmacol Sci 2010; 31 (2): 89-98.
10. Hursting SD, Kari FW,. The anti-carcinogenic effects of dietary restriction: Mechanisms and future directions. Mutat Res 1999; 443 (1-2): 235-249.
11. Rodriguez C, Freedland SJ, Deka A, Jacobs EJ, McCullough ML, Patel AV, Thun MJ, Calle EE,. Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 2007; 16 (1): 63-69.
12. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, Sinclair DA,. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006; 444 (7117): 337-342.
13. Barger JL, Kayo T, Vann JM, Arias EB, Wang J, Hacker TA, Wang Y, Raederstorff D, Morrow JD, Leeuwenburgh C, Allison DB, Saupe KW, Cartee GD, Weindruch R, Prolla TA,. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS ONE 2008; 3 (6): e2264.
14. Calamini B, Ratia K, Malkowski MG, Cuendet M, Pezzuto JM, Santarsiero BD, Mesecar AD,. Pleiotropic mechanisms facilitated by resveratrol and its metabolites. Biochem J 2010; 429 (2): 273-282.
15. Hursting SD, Lavigne JA, Berrigan D, Perkins SN, Barrett JC,. Calorie restriction, aging, and cancer prevention: Mechanisms of action and applicability to humans. Annu Rev Med 2003; 54: 131-152.
16. Gennigens C, Menetrier-Caux C, Droz JP,. Insulin-Like Growth Factor (IGF) family and prostate cancer. Crit Rev Oncol Hematol 2006; 58 (2): 124-145.
17. Jung-Hynes B, Schmit TL, Reagan-Shaw SR, Siddiqui IA, Mukhtar H, Ahmad N,. Melatonin, a novel Sirt1 inhibitor, imparts antiproliferative effects against prostate cancer in vitro in culture and in vivo in TRAMP model. J Pineal Res 2011; 50 (2): 140-149.
18. Thomas JA 2nd, Antonelli JA, Lloyd JC, Masko EM, Poulton SH, Phillips TE, Pollak M, Freedland SJ,. Effect of intermittent fasting on prostate cancer tumor growth in a mouse model. Prostate Cancer Prostatic Dis 2010; 13 (4): 350-355.
19. Freedland SJ, Mavropoulos J, Wang A, Darshan M, Demark-Wahnefried W, Aronson WJ, Cohen P, Hwang D, Peterson B, Fields T, Pizzo SV, Isaacs WB,. Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis. Prostate 2008; 68 (1): 11-19.
20. Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK,. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004; 32 (12): 1377-1382.
21. Yakar S, Bouxsein ML, Canalis E, Sun H, Glatt V, Gundberg C, Cohen P, Hwang D, Boisclair Y, Leroith D, Rosen CJ,. The ternary IGF complex influences postnatal bone acquisition and the skeletal response to intermittent parathyroid hormone. J Endocrinol 2006; 189 (2): 289-299.
22. Watson CS, Bialek P, Anzo M, Khosravi J, Yee SP, Han VK,. Elevated circulating insulin-like growth factor binding protein-1 is sufficient to cause fetal growth restriction. Endocrinology 2006; 147 (3): 1175-1186.
23. Vanzulli S, Gazzaniga S, Braidot MF, Vecchi A, Mantovani A, Wainstok de Calmanovici R,. Detection of endothelial cells by MEC 13.3 monoclonal antibody in mice mammary tumors. Biocell 1997; 21 (1): 39-46.
24. Vecchi A, Garlanda C, Lampugnani MG, Resnati M, Matteucci C, Stoppacciaro A, Schnurch H, Risau W, Ruco L, Mantovani A, et al. Monoclonal antibodies specific for endothelial cells of mouse blood vessels. Their application in the identification of adult and embryonic endothelium. Eur J Cell Biol 1994; 63 (2): 247-254.
25. Rasband WS, Image J,. Bethesda, Maryland, USA: National Institutes of Health; 2008.
26. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP,. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003; 31 (4): e15.
27. Bolstad BM, Irizarry RA, Astrand M, Speed TP,. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003; 19 (2): 185-193.
28. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J,. Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol 2004; 5 (10): R80.
29. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP,. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005; 102 (43): 15545-15550.
30. Johnson WE, Li C, Rabinovic A,. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007; 8 (1): 118-127.
31. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, Olson JA Jr, Marks JR, Dressman HK, West M, Nevins JR,. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006; 439 (7074): 353-357.
32. Mendiratta P, Mostaghel E, Guinney J, Tewari AK, Porrello A, Barry WT, Nelson PS, Febbo PG,. Genomic strategy for targeting therapy in castration-resistant prostate cancer. J Clin Oncol 2009; 27 (12): 2022-2029.
33. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ, Lucia MS,. Molecular characterization of human prostate carcinoma cell lines. Prostate 2003; 57 (3): 205-225.
34. van Bokhoven A, Varella-Garcia M, Korch C, Hessels D, Miller GJ,. Widely used prostate carcinoma cell lines share common origins. Prostate 2001; 47 (1): 36-51.
35. Nan B, Snabboon T, Unni E, Yuan XJ, Whang YE, Marcelli M,. The PTEN tumor suppressor is a negative modulator of androgen receptor transcriptional activity. J Mol Endocrinol 2003; 31 (1): 169-183.
36. Carroll AG, Voeller HJ, Sugars L, Gelmann EP,. p53 oncogene mutations in three human prostate cancer cell lines. Prostate 1993; 23 (2): 123-134.
37. Isaacs WB, Carter BS, Ewing CM,. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 1991; 51 (17): 4716-4720.
38. Dong JT,. Prevalent mutations in prostate cancer. J Cell Biochem 2006; 97 (3): 433-447.
39. Jung-Hynes B, Nihal M, Zhong W, Ahmad N,. Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition? J Biol Chem 2009; 284 (6): 3823-3832.
40. Foster CS, Falconer A, Dodson AR, Norman AR, Dennis N, Fletcher A, Southgate C, Dowe A, Dearnaley D, Jhavar S, Eeles R, Feber A, Cooper CS,. Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome. Oncogene 2004; 23 (35): 5871-5879.
41. Yardy GW, Brewster SF,. THE Wnt signalling pathway is a potential therapeutic target in prostate cancer. BJU Int 2006; 98 (4): 719-721.
42. Fukui M, Yamabe N, Kang KS, Zhu BT,. Growth-stimulatory effect of resveratrol in human cancer cells. Mol Carcinog 2010; 49 (8): 750-759.
43. Ngo TH, Barnard RJ, Cohen P, Freedland S, Tran C, deGregorio F, Elshimali YI, Heber D, Aronson WJ,. Effect of isocaloric low-fat diet on human LAPC-4 prostate cancer xenografts in severe combined immunodeficient mice and the insulin-like growth factor axis. Clin Cancer Res 2003; 9 (7): 2734-2743.
44. Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO,. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 1997; 76 (9): 1115-1118.
45. Wolk A, Mantzoros CS, Andersson SO, Bergstrom R, Signorello LB, Lagiou P, Adami HO, Trichopoulos D,. Insulin-like growth factor 1 and prostate cancer risk: A population-based, case-control study. J Natl Cancer Inst 1998; 90 (12): 911-915.
46. Buschemeyer WCJ 3rd, Klink JC, Mavropoulos JC, Poulton SH, Demark-Wahnefried W, Hursting SD, Cohen P, Hwang D, Johnson TL, Freedland SJ,. Effect of intermittent fasting with or without caloric restriction on prostate cancer growth and survival in SCID mice. Prostate 2010; 70 (10): 1037-1043.
47. Kapetanovic IM, Muzzio M, Huang Z, Thompson TN, McCormick DL,. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother Pharmacol 2011; 68 (3): 593-601.